TYPE 1 VS TYPE 2 RESPIRATORY FAILURE
Respiratory failure occurs when the respiratory system can no longer maintain adequate gas exchange to meet the metabolic demands of the body. It is broadly classified into Type 1 (hypoxaemic) and Type 2 (hypercapnic) respiratory failure, based on the primary gas exchange abnormality.
Although both forms can coexist in advanced disease, distinguishing between Type 1 and Type 2 respiratory failure is essential for understanding the underlying pathophysiology and anticipating clinical deterioration. Each type reflects a different failure within the respiratory system—either oxygenation or ventilation.
What You Need to Know
Respiratory failure occurs when the respiratory system can no longer maintain adequate gas exchange. It is broadly classified into Type 1 and Type 2 respiratory failure based on arterial blood gas patterns and the underlying physiological disturbance. Although both forms may coexist in advanced disease, the mechanisms that drive them are distinct and have important implications for assessment and management.
Type 1 respiratory failure is defined by hypoxaemia, meaning low arterial oxygen levels, with normal or low carbon dioxide levels. The core problem is failure of oxygen transfer from the alveoli into the pulmonary capillary blood. Ventilation may be adequate or even increased, but abnormalities at the alveolar or pulmonary vascular level prevent effective oxygen diffusion. Common mechanisms include alveolar filling, alveolar collapse, diffusion limitation, or ventilation–perfusion mismatch.
Key physiological features of Type 1 respiratory failure include:
Impaired oxygenation due to alveolar or capillary pathology
Normal or low PaCO₂, often due to compensatory hyperventilation
Poor response to exertion, with oxygen levels falling further during activity
Type 1 respiratory failure is commonly seen in conditions such as pneumonia, acute respiratory distress syndrome, pulmonary oedema, pulmonary embolism, and interstitial lung disease. Patients often present with marked hypoxaemia and increased work of breathing, while carbon dioxide levels remain normal because CO₂ diffuses more readily and ventilation is preserved.
Type 2 respiratory failure is characterised by hypercapnia, meaning elevated arterial carbon dioxide levels, usually accompanied by hypoxaemia. In this form, the fundamental problem is inadequate alveolar ventilation. Carbon dioxide retention reflects failure of the respiratory pump, airway obstruction, or impaired central respiratory drive. Unlike Type 1 failure, the lungs may be capable of gas exchange, but insufficient air reaches the alveoli to remove CO₂ effectively.
Key physiological features of Type 2 respiratory failure include:
Elevated PaCO₂, indicating inadequate ventilation
Associated hypoxaemia, due to reduced alveolar oxygen delivery
Ventilatory failure, rather than primary diffusion or perfusion abnormality
Type 2 respiratory failure occurs in conditions such as chronic obstructive pulmonary disease, severe asthma, neuromuscular disorders, chest wall deformities, obesity hypoventilation syndrome, and drug-induced respiratory depression. As carbon dioxide rises, respiratory acidosis develops, which can impair cardiac function, reduce cerebral perfusion, and depress consciousness. In contrast to Type 1 failure, oxygen therapy alone may worsen hypercapnia if ventilation is not simultaneously supported.
Beyond the Basics
Type 1 Respiratory Failure: Failure of Oxygenation
Type 1 respiratory failure develops when oxygen cannot be transferred effectively from the alveoli into the pulmonary capillary blood. The underlying problem lies at the level of the alveoli or pulmonary circulation rather than in the mechanics of breathing. Alveoli may be filled with fluid, collapsed, inflamed, thickened, or inadequately perfused, all of which interfere with normal oxygen diffusion across the alveolar–capillary membrane.
The most common mechanism is ventilation–perfusion mismatch. In this situation, blood continues to flow through parts of the lung that are poorly ventilated, resulting in reduced arterial oxygen levels. As disease severity increases, intrapulmonary shunting may occur, where blood passes through completely non-ventilated alveoli. Because this blood never comes into contact with oxygen, hypoxaemia is often severe and responds poorly to supplemental oxygen. This explains why oxygen therapy alone may be insufficient in advanced alveolar disease.
Conditions such as pneumonia, acute respiratory distress syndrome, pulmonary embolism, and interstitial lung disease commonly produce Type 1 respiratory failure. In these settings, carbon dioxide levels are often normal or reduced. Carbon dioxide diffuses more readily than oxygen, and patients typically increase their respiratory rate in response to hypoxaemia, allowing CO₂ to be eliminated despite impaired oxygen transfer.
Type 2 Respiratory Failure: Failure of Ventilation
Type 2 respiratory failure occurs when alveolar ventilation is inadequate to remove the carbon dioxide produced by normal metabolism. The defining abnormality is carbon dioxide retention, leading to hypercapnia and respiratory acidosis. In contrast to Type 1 failure, the alveoli themselves may be capable of gas exchange, but insufficient air reaches them to maintain effective ventilation.
Several mechanisms can impair ventilation. Airway obstruction, as seen in chronic obstructive pulmonary disease or severe asthma, limits expiratory flow and causes air trapping, reducing effective alveolar ventilation. Neuromuscular weakness affects the ability of respiratory muscles to generate sufficient force, while disorders of respiratory drive reduce the neural signals required to sustain breathing. Excessive respiratory muscle fatigue can also develop when the work of breathing is persistently elevated.
As carbon dioxide accumulates, alveolar oxygen tension falls, leading to secondary hypoxaemia. For this reason, Type 2 respiratory failure usually involves both hypercapnia and hypoxaemia. The rise in carbon dioxide has important systemic effects, including cerebral vasodilation, reduced level of consciousness, and impaired myocardial contractility, which can further worsen clinical status.
Differences in Compensation and Disease Progression
The physiological response to respiratory failure differs between the two types. In Type 1 respiratory failure, patients often present with marked tachypnoea as the body attempts to improve oxygenation by increasing minute ventilation. Despite this increased effort, oxygen levels improve only minimally because the fundamental problem lies in diffusion or perfusion rather than ventilation.
In Type 2 respiratory failure, the pattern of compensation depends on whether carbon dioxide retention is acute or chronic. Acute hypercapnia produces rapid respiratory acidosis, leading to headache, confusion, agitation, or reduced consciousness. In chronic conditions such as advanced COPD, renal compensation occurs over time through retention of bicarbonate, partially normalising pH despite persistently elevated carbon dioxide levels. This adaptation can mask the severity of ventilatory failure until a superimposed insult causes sudden decompensation.
Overlap and Mixed Respiratory Failure
In advanced respiratory disease, Type 1 and Type 2 respiratory failure frequently coexist. Severe COPD exacerbations may initially present with hypoxaemia due to ventilation–perfusion mismatch and later progress to carbon dioxide retention as respiratory muscles fatigue. Similarly, conditions such as ARDS may begin as isolated hypoxaemic failure and evolve into hypercapnic failure as lung compliance deteriorates and effective ventilation becomes increasingly difficult.
Recognising which mechanism predominates at a given time is essential for interpreting blood gas results, anticipating deterioration, and guiding escalation of respiratory support. Mixed respiratory failure reflects advanced physiological compromise and often signals the need for ventilatory assistance rather than oxygen therapy alone.
Clinical Connections
Type 1 respiratory failure most often presents with dyspnoea and tachypnoea driven by hypoxaemia and increased respiratory drive. Oxygen saturation may remain low despite supplemental oxygen, particularly when intrapulmonary shunt or severe ventilation–perfusion mismatch is present. Cyanosis can occur when arterial oxygen levels fall significantly, while mental status is usually preserved until hypoxia becomes profound. The presence of severe breathlessness with relatively normal carbon dioxide levels reflects preserved ventilation despite failure of oxygen transfer.
Type 2 respiratory failure produces a different clinical pattern because carbon dioxide retention directly affects the central nervous system. Headache, confusion, drowsiness, agitation, or reduced level of consciousness are common features and may progress rapidly in acute hypercapnia. Signs of increased work of breathing, such as accessory muscle use, paradoxical abdominal movement, and visible fatigue, often indicate impending ventilatory failure. Hypoxaemia is frequently present but is secondary to inadequate ventilation rather than primary alveolar disease.
Key clinical distinctions that help identify the dominant mechanism include:
Predominant hypoxaemia with marked tachypnoea and preserved consciousness, suggesting Type 1 failure
Neurological symptoms with elevated carbon dioxide and respiratory acidosis, indicating Type 2 failure
Escalating work of breathing and fatigue, signalling progression toward mixed or ventilatory failure
Interpretation of arterial blood gases is central to differentiation and ongoing assessment. Trends in oxygenation, carbon dioxide levels, and pH provide insight into disease progression and the effectiveness of therapy. Worsening hypoxaemia despite oxygen therapy suggests shunt physiology, while rising carbon dioxide and falling pH indicate failing ventilation. Recognising transition from isolated Type 1 or Type 2 respiratory failure to mixed failure is critical, as this often marks the point where ventilatory support rather than oxygen therapy alone becomes necessary.
Concept Check
Why can Type 1 respiratory failure occur despite normal or increased ventilation?
How does ventilation–perfusion mismatch differ from intrapulmonary shunting?
Why is carbon dioxide retention the defining feature of Type 2 respiratory failure?
How does chronic hypercapnia alter acid–base compensation?
Why do many severe respiratory conditions progress from Type 1 to mixed respiratory failure?